Sandoz Shares Rise Over 2% After $322 Million Biosimilar Deal with Henlius

Sandoz stock rose more than 2% after a strategic deal with Henlius covering up to 10 biosimilars worth up to $322 million, expanding its pipeline to 39 assets with potential for 46.

Sandoz shares climbed more than 2% on Monday after the Swiss generic drugmaker announced a strategic collaboration with Shanghai Henlius Biotech covering up to 10 biosimilars. The milestone-based deal is worth up to $322 million and expands Sandoz’s industry-leading pipeline to 39 assets, with potential to reach 46.

Sandoz and Henlius Sign $322M Global Biosimilars Deal 

Under the agreement announced on August 17, 2026, Sandoz gains global commercialization rights outside China for the partnered biosimilars, while Henlius is responsible for development and manufacturing. Total potential payments reach $322 million, with near-term payments linked to the initial assets of up to $100.5 million.

Initial assets include a proposed biosimilar to cetuximab (Erbitux, used in metastatic colorectal cancer and head and neck cancer), a proposed biosimilar to evolocumab (Repatha, for high cholesterol and cardiovascular risk reduction), and a proposed biosimilar to belimumab (Benlysta, for lupus). Sandoz also holds an option on a recombinant human hyaluronidase to aid absorption of injected medicines.

The evolocumab and hyaluronidase candidates are in technical development; the belimumab biosimilar is in early-stage development. The collaboration expands an existing 2025 oncology partnership between the companies that already covered an ipilimumab biosimilar.

Jefferies analysts noted the deal supports further in-licensing activity and includes a risk-adjusted value of CHF 3.3 per share in their street-high CHF 93 price target. Further details are expected at Sandoz’s Capital Markets Day on September 8.

Investors Back Sandoz’s Expanded Biosimilar Strategy 

Investors welcomed the expansion of Sandoz’s biosimilar pipeline at a time when large loss-of-exclusivity opportunities are emerging over the next decade. The deal is one of Sandoz’s largest-ever biosimilar collaborations and reinforces its strategy to capture a significant share of the global biosimilars market. Positive analyst commentary and the near-term payment visibility supported the share-price rise.

Sandoz Targets $4.6B+ Biosimilar Market Opportunity 

Sandoz is a global leader in generics and biosimilars. Biosimilars are highly similar versions of approved biologic medicines and offer lower-cost alternatives once originator patents expire. Colorectal cancer is the third most common cancer diagnosis and second-leading cause of cancer death worldwide; head and neck cancers account for roughly one million new cases annually. Originator sales for the reference products are substantial: Erbitux generated about €1.18 billion in 2025, Repatha $1.66 billion, and Benlysta £1.77 billion.

Investors Eye September 8 for Sandoz’s Next Growth Signals 

Markets will look for additional details at Sandoz’s Capital Markets Day on September 8. Progress on the initial assets through development and regulatory milestones, plus any further in-licensing deals, will be closely watched as indicators of long-term growth.